| P50 | author | Abel Santamaría | Q88868534 |
| P2093 | author name string | Paul Carrillo-Mora | |
| | Verónica Pérez-De la Cruz | |
| P2860 | cites work | Interaction of the nuclear matrix protein NAKAP with HypA and huntingtin: implications for nuclear toxicity in Huntington's disease pathogenesis | Q24300257 |
| | A huntingtin-associated protein enriched in brain with implications for pathology | Q24303499 |
| | Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity | Q24337727 |
| | Excitotoxic damage, disrupted energy metabolism, and oxidative stress in the rat brain: antioxidant and neuroprotective effects of L-carnitine | Q46808934 |
| | Pyruvate and lactate protect striatal neurons against N-methyl-D-aspartate-induced neurotoxicity | Q48098641 |
| | Mechanism of kainate toxicity to cerebellar neurons in vitro is analogous to reperfusion tissue injury | Q48202227 |
| | Ultrastructural changes in brain parenchyma during normal aging and in animal models of aging | Q48226572 |
| | Evidence that quinolinic acid severely impairs energy metabolism through activation of NMDA receptors in striatum from developing rats. | Q48306465 |
| | In vitro effect of quinolinic acid on energy metabolism in brain of young rats | Q48358256 |
| | Cyanide-induced generation of oxidative species: involvement of nitric oxide synthase and cyclooxygenase-2. | Q48472258 |
| | Brain mitochondrial defects amplify intracellular [Ca2+] rise and neurodegeneration but not Ca2+ entry during NMDA receptor activation. | Q48600704 |
| | ATP as a marker of excitotoxin-induced nerve cell death in vivo | Q70041527 |
| | Isolated cerebral and cerebellar mitochondria produce free radicals when exposed to elevated CA2+ and Na+: implications for neurodegeneration | Q72069850 |
| | Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid | Q72098398 |
| | Zinc-induced cortical neuronal death: contribution of energy failure attributable to loss of NAD(+) and inhibition of glycolysis | Q73704452 |
| | Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization | Q95810356 |
| | The uncoupling agent 2,4-dinitrophenol improves mitochondrial homeostasis following striatal quinolinic acid injections | Q46765141 |
| | The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis | Q24616907 |
| | A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. | Q27860836 |
| | Genetic interaction between expanded murine Hdh alleles and p53 reveal deleterious effects of p53 on Huntington's disease pathogenesis | Q28507529 |
| | Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro | Q28584697 |
| | HAP1 facilitates effects of mutant huntingtin on inositol 1,4,5-trisphosphate-induced Ca release in primary culture of striatal medium spiny neurons | Q28592352 |
| | Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators | Q29617353 |
| | Mitochondrial control of cell death | Q29617739 |
| | N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking | Q30486372 |
| | Effects of overexpression of huntingtin proteins on mitochondrial integrity | Q30489322 |
| | Mitochondria in neurodegeneration: bioenergetic function in cell life and death | Q33541512 |
| | Role of protein phosphatases and mitochondria in the neuroprotective effects of estrogens | Q33715371 |
| | Replicating Huntington's disease phenotype in experimental animals | Q33749061 |
| | Mitochondrial dysfunction in the pathogenesis of necrotic and apoptotic cell death | Q33832682 |
| | Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription | Q33916580 |
| | A polymorphic DNA marker genetically linked to Huntington's disease | Q34255139 |
| | The energetics of Huntington's disease | Q34308028 |
| | Behavioral characterization of quinolinate-induced lesions of the medial striatum: relevance for Huntington's disease | Q34374332 |
| | Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? | Q35254212 |
| | Selective defect of in vivo glycolysis in early Huntington's disease striatum | Q35634060 |
| | Mitochondrial DNA damage is a hallmark of chemically induced and the R6/2 transgenic model of Huntington's disease | Q35706627 |
| | The epidemiology of Huntington's disease | Q35882166 |
| | Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation | Q36255989 |
| | Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity | Q36320596 |
| | Hypothesis: Huntingtin may function in membrane association and vesicular trafficking | Q36704515 |
| | 3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin. | Q36934346 |
| | Mitochondrial structural and functional dynamics in Huntington's disease | Q37356257 |
| | 3-Nitropropionic acid as a tool to study the mechanisms involved in Huntington's disease: past, present and future. | Q37718532 |
| | Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation | Q38720406 |
| | Mitochondrial-dependent apoptosis in Huntington's disease human cybrids. | Q39751441 |
| | Oxidative stress and plasma aminopeptidase activity in Huntington's disease | Q39907630 |
| | Calcium homeostasis and mitochondrial dysfunction in striatal neurons of Huntington disease | Q40031554 |
| | Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington's disease patients | Q40207281 |
| | Mutant huntingtin expression induces mitochondrial calcium handling defects in clonal striatal cells: functional consequences | Q40231756 |
| | Severe ultrastructural mitochondrial changes in lymphoblasts homozygous for Huntington disease mutation | Q40351019 |
| | Huntingtin associates with acidic phospholipids at the plasma membrane | Q40387540 |
| | The early events of oxygen and glucose deprivation: setting the scene for neuronal death? | Q40392008 |
| | Ca2+-induced permeability transition in human lymphoblastoid cell mitochondria from normal and Huntington's disease individuals. | Q40443282 |
| | Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release | Q40551652 |
| | Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease. | Q40661429 |
| | Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. | Q40721588 |
| | Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription | Q40764541 |
| | Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release | Q40808988 |
| | The possible contribution of microglia and macrophages to delayed neuronal death after ischemia | Q40882185 |
| | Regional mitochondrial respiratory activity in Huntington's disease brain | Q41360902 |
| | Complex II inhibition by 3-NP causes mitochondrial fragmentation and neuronal cell death via an NMDA- and ROS-dependent pathway. | Q41969689 |
| | Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. | Q42438521 |
| | Energetic dysfunction in quinolinic acid-lesioned rat striatum | Q42445269 |
| | Excitotoxic brain damage involves early peroxynitrite formation in a model of Huntington's disease in rats: protective role of iron porphyrinate 5,10,15,20-tetrakis (4-sulfonatophenyl)porphyrinate iron (III). | Q42482897 |
| | Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues | Q42503942 |
| | Cellular and subcellular localization of Huntingtin [corrected] aggregates in the brain of a rat transgenic for Huntington disease | Q42508306 |
| | Cytoplasmic calcium mediates oxidative damage in an excitotoxic /energetic deficit synergic model in rats. | Q42526044 |
| | Antioxidant strategy to rescue synaptosomes from oxidative damage and energy failure in neurotoxic models in rats: protective role of S-allylcysteine | Q43252987 |
| | 3-nitropropionic acid-induced mitochondrial permeability transition: comparative study of mitochondria from different tissues and brain regions | Q43268781 |
| | Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease | Q43669934 |
| | Oxidative damage and metabolic dysfunction in experimental Huntington's disease: selective vulnerability of the striatum and hippocampus. | Q43731488 |
| | Pyramidal cell loss in motor cortices in Huntington's disease | Q44149293 |
| | Cyanide induces different modes of death in cortical and mesencephalon cells | Q44186026 |
| | In vitro effects of polyglutamine tracts on Ca2+-dependent depolarization of rat and human mitochondria: relevance to Huntington's disease. | Q44298045 |
| | Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice | Q44316963 |
| | Influence of cytosolic and mitochondrial Ca2+, ATP, mitochondrial membrane potential, and calpain activity on the mechanism of neuron death induced by 3-nitropropionic acid | Q44348986 |
| | Neuroprotective effects of pyruvate in the quinolinic acid rat model of Huntington's disease | Q44614374 |
| | Protective effect of melatonin on 3-nitropropionic acid-induced oxidative stress in synaptosomes in an animal model of Huntington's disease | Q45107385 |
| | 3-nitropropionic acid-induced hydrogen peroxide, mitochondrial DNA damage, and cell death are attenuated by Bcl-2 overexpression in PC12 cells | Q45264432 |
| | Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. | Q45291767 |
| | Targeting oxidative/nitrergic stress ameliorates motor impairment, and attenuates synaptic mitochondrial dysfunction and lipid peroxidation in two models of Huntington's disease | Q45292072 |
| | Treatment with dehydroepiandrosterone prevents oxidative stress induced by 3-nitropropionic acid in synaptosomes | Q45292543 |
| | Degeneration of pyramidal projection neurons in Huntington's disease cortex | Q45294227 |
| | Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. | Q45294680 |
| | Clinical Genetics, II. Huntington's disease: from the gene to pathophysiology | Q45294788 |
| | Hyperactivity and hypoactivity in a rat model of Huntington's disease: the systemic 3-nitropropionic acid model | Q45295346 |
| | 1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers | Q45296001 |
| | Distribution of phosphate-activated glutaminase, succinic dehydrogenase, pyruvate dehydrogenase and gamma-glutamyl transpeptidase in post-mortem brain from Huntington's disease and agonal cases | Q45296514 |
| | Glyceraldehyde 3-phosphate dehydrogenase abnormality in metabolically stressed Huntington disease fibroblasts. | Q45296630 |
| | Brain glyceraldehyde-3-phosphate dehydrogenase activity in human trinucleotide repeat disorders | Q45296636 |
| | Biochemical abnormalities and excitotoxicity in Huntington's disease brain. | Q45297145 |
| | Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin | Q45297269 |
| | p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease | Q45297400 |
| | HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism | Q45298206 |
| | Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins | Q45298596 |
| | 3-nitropropionic acid induced in vivo protein oxidation in striatal and cortical synaptosomes: insights into Huntington's disease | Q45299994 |
| | Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons | Q45300079 |
| | Increased apoptosis, Huntingtin inclusions and altered differentiation in muscle cell cultures from Huntington's disease subjects | Q45301339 |
| | Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. | Q45302702 |
| | Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration | Q45302924 |
| | Wild-type huntingtin participates in protein trafficking between the Golgi and the extracellular space | Q45303717 |
| | Cerebral metabolism and atrophy in huntington's disease determined by18FDG and computed tomographic scan | Q45304491 |
| | Huntington's disease and mitochondrial DNA deletions: event or regular mechanism for mutant huntingtin protein and CAG repeats expansion?! | Q45306758 |
| | Mitochondrial NAD+-linked State 3 respiration and complex-I activity are compromised in the cerebral cortex of 3-nitropropionic acid-induced rat model of Huntington's disease. | Q45306770 |
| | Early nerve ending rescue from oxidative damage and energy failure by L: -carnitine as post-treatment in two neurotoxic models in rat: recovery of antioxidant and reductive capacities. | Q45946973 |
| | Possible role of sertraline against 3-nitropropionic acid induced behavioral, oxidative stress and mitochondrial dysfunctions in rat brain | Q46235939 |
| | Melatonin protects against neuronal damage induced by 3-nitropropionic acid in rat striatum | Q46480941 |
| | Krebs cycle intermediates modulate thiobarbituric acid reactive species (TBARS) production in rat brain in vitro. | Q46492101 |
| | Quinolinate-induced rat striatal excitotoxicity impairs endoplasmic reticulum Ca2+-ATPase function | Q46728440 |
| P433 | issue | 3 | |
| P921 | main subject | Huntington's disease | Q190564 |
| P304 | page(s) | 207-215 | |
| P577 | publication date | 2010-06-01 | |
| P1433 | published in | Journal of Bioenergetics and Biomembranes | Q5044470 |
| P1476 | title | Huntington's disease and mitochondrial alterations: emphasis on experimental models | |
| P478 | volume | 42 | |